Seize Golden Chance To Facilitate Your Market Access To China: Shanghai Launched Several Favorable Measures For Overseas MedTech Companies
In order to support the development of biomedical R&D economy, Shanghai Municipal Drug Administration issued a number of policy measures to accelerate the development of global biomedical R&D economy and industrialization on November 21, 2022.
Main Objective
By 2025, the development pattern of global biomedical R&D economy and industrialization will be initially formed; The overall scale of the R&D economy reached over 100 billion yuan; Cultivate or introduce more than 100 blockbuster products of innovative medical devices; Cultivate more than 50 innovative headquarters with multiple functions of biomedical R&D, sales and settlement; More than 20 high-level biomedicine incubators and accelerators will be cultivated.
By 2030, Shanghai’s position in global biomedical R&D economy and industrialization will be further highlighted. A number of innovative drugs and medical devices that are developed and listed in Shanghai will emerge, and a number of innovative biomedical headquarters and innovation platforms with domestic and international influence will be gathered.
Policy Highlights
-
Enhance capacity for R&D and innovation;
-
Support new models of R&D and production of innovative drugs and medical devices;
-
Introduce and cultivate innovative headquarters;
-
Support the construction of high-level incubation and transformation platforms;
-
Increase the activity of biomedical intellectual property trading;
-
Support the launch and use of R&D innovative products;